Edition:
United Kingdom

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

5,970JPY
6:00am GMT
Change (% chg)

¥40 (+0.67%)
Prev Close
¥5,930
Open
¥5,870
Day's High
¥5,990
Day's Low
¥5,870
Volume
667,600
Avg. Vol
854,126
52-wk High
¥6,020
52-wk Low
¥3,280

Latest Key Developments (Source: Significant Developments)

CHUGAI PHARMACEUTICAL says filing of patent infringement lawsuit and petition for provisional disposition order
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - CHUGAI PHARMACEUTICAL Co Ltd <4519.T> ::Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd.Says the company has also filed an application for assisting intervention in a petition for provisional disposition order that has been filed with the lawsuit.  Full Article

Chiome Bioscience says termination of joint research contract
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Chiome Bioscience Inc <4583.T>:Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD <<<4519.T>>>, as the contract has expired on Dec. 31 .  Full Article

Chugai Pharmaceutical says change of chief executive officer
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018.  Full Article

R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I.Says rating outlook stable -R&I.  Full Article

Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it and TAIYO HOLDINGS CO LTD <<<4626.T>>> announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings.  Full Article

Chugai Pharmaceutical to retire treasury shares
Tuesday, 25 Apr 2017 

April 25(Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it will retire 123,000 shares (0.02 percent of outstanding) of its common stock on April 28.  Full Article

Chugai and Galderma announce global license agreement for Nemolizumab
Thursday, 21 Jul 2016 

Chugai Pharmaceutical Co Ltd <4519.T>: Chugai will continue to be responsible for product manufacturing and supply of Nemolizumab. . Under terms of agreement, Chugai will receive an upfront, milestone and royalty payments from Galderma. . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases . Chugai and Galderma announce global license agreement for Nemolizumab (cim331), novel biologic for skin diseases .Chugai will grant Galderma license for development and marketing of nemolizumab worldwide, exception of Japan and Taiwan.  Full Article

Chugai Pharmaceutical says concluded a license agreement with Roche
Wednesday, 1 Jun 2016 

Chugai Pharmaceutical Co Ltd: Announced that it concluded a license agreement with roche for "sa237" .Per the terms of the agreement, chugai will receive an upfront fee, milestone and royalty payments from roche..  Full Article

Six Japanese drugmakers will team up to discover new cancer, depression treatments - Nikkei
Wednesday, 25 May 2016 

Nikkei: Astellas Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharmaceutical,Chugai Pharmaceutical will collaborate with 4 research institutions - Nikkei . The Six Drugmakers will work with research organizations providing cell, tissue samples to discover new pharmaceuticals - Nikkei . Around 3 billion Yen ($27.2 Million) will be put into drug-discovery efforts by fiscal 2019 - Nikkei .Group will create five teams looking into treatments for cancer, diabetic nephropathy and mental illnesses including depression - Nikkei.  Full Article

Chugai Pharmaceutical announces results of Japanese phase III study of Alecensa
Thursday, 19 May 2016 

Chugai Pharmaceutical Co Ltd : Announced results of Japanese phase III study of Alecensa in Alk fusion gene positive non-small cell lung cancer .PFS hazard ratio of Alecensa arm to Crizotinib arm was 0.34 and Alecensa demonstrated significantly prolonged PFS.  Full Article

Swiss stocks - Factors to watch on Jan 19

ZURICH, Jan 19 The Swiss blue-chip SMI was seen opening 0.13 percent lower at 9,440 points on Friday, according to premarket indications by bank Julius Baer .